Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 …

…, R Foa, N Gökbuget, AH Goldstone, N Goulden… - Leukemia, 2010 - nature.com
Assessment of minimal residual disease (MRD) has acquired a prominent position in European
treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of …

[HTML][HTML] Meditation programs for psychological stress and well-being: a systematic review and meta-analysis

M Goyal, S Singh, EMS Sibinga, NF Gould… - JAMA internal …, 2014 - jamanetwork.com
Importance Many people meditate to reduce psychological stress and stress-related health
problems. To counsel people appropriately, clinicians need to know what the evidence says …

The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis

N Cooper, K Rao, N Goulden, D Webb… - Bone marrow …, 2008 - nature.com
… There were four TRMs from CMV pneumonitis (n=1), multifactorial pneumonitis following T …
(n=1), para-influenza pneumonitis (n=1) and hepatic rupture post-transjugular liver biopsy (n=…

The salience network is responsible for switching between the default mode network and the central executive network: replication from DCM

N Goulden, A Khusnulina, NJ Davis, RM Bracewell… - Neuroimage, 2014 - Elsevier
With the advent of new analysis methods in neuroimaging that involve independent component
analysis (ICA) and dynamic causal modelling (DCM), investigations have focused on …

[HTML][HTML] Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a …

A Vora, N Goulden, R Wade, C Mitchell… - The lancet …, 2013 - thelancet.com
Background Minimal residual disease (MRD) is the most sensitive and specific predictor of
relapse risk in children with acute lymphoblastic leukaemia (ALL) during remission. We …

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

…, K Rao, D Bonney, S Samarasinghe, N Goulden… - Nature medicine, 2019 - nature.com
… Data are representative of independent samples taken at multiple time points from n = 13
patients. b, The percentage of CAR T cells within the T cell compartment of the peripheral …

[HTML][HTML] Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

…, M Morgan, A Masurekar, N Goulden, N Green… - The Lancet, 2010 - thelancet.com
Background Although survival of children with acute lymphoblastic leukaemia has improved
greatly in the past two decades, the outcome of those who relapse has remained static. We …

Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation

…, ABM Foot, D Grier, JM Cornish, N Goulden… - Bone marrow …, 2000 - nature.com
We conducted a retrospective review of the clinical features and outcome of adenovirus
infection in 572 consecutive patients transplanted in a single centre over a 10 year period. One …

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and …

A Vora, N Goulden, C Mitchell, J Hancock… - The lancet …, 2014 - thelancet.com
… 533 MRD high-risk patients were randomly assigned to receive standard (n=266) or
augmented (n=267) post-remission therapy. After a median follow-up of 70 months (IQR 52–91), 5-…

Characterization of acute lymphoblastic leukemia progenitor cells

…, RS Evely, A Oakhill, DH Pamphilon, NJ Goulden… - Blood, 2004 - ashpublications.org
… Cells from the remaining 17 patients who either had a normal karyotype (n = 10) or for whom
FISH probes were not available (n = 7) were evaluated by routine morphologic analyses. In …